Dallas, Texas (PRWEB) October 20, 2014
This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects.
Partial Seizures are seizures which affect initially only one hemisphere of the brain. The brain is divided into two hemispheres, each consisting of four lobes – the frontal, temporal, parietal and occipital lobes. In partial seizures the seizure is generated in and affects just one part of the brain – the whole hemisphere or part of a lobe. Symptoms will vary according to where the seizure occurs. In the frontal lobe symptoms may include a wave-like sensation in the head; in the temporal lobe, a feeling of déjà vu; in the parietal lobe, a numbness or tingling; and in the occipital lobe, visual disturbance or hallucination. Partial seizures are split into two main categories; simple partial seizures and complex partial seizures.
Complete report available @ http://www.rnrmarketresearch.com/partial-seizure-pipeline-review-h2-2014-market-report.html .
In simple partial seizures a small part of one of the lobes may be affected and the person remains conscious. This will often be a precursor to a larger seizure such as a complex partial seizure. When this is the case, the simple partial seizure is usually called an aura. A complex partial seizure affects a larger part of the hemisphere than a simple partial seizure and the person may lose consciousness. If a partial seizure spreads from one hemisphere to the other side of the brain, this will give rise to a secondarily generalised seizure. The person will become unconscious and may well have a tonic clonic seizure.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=231459 .
Partial Seizure - Companies Involved in Therapeutics Development:
- Novartis AG
- Eisai Co., Ltd.
- Pfizer Inc.
- UCB S.A.
- Marinus Pharmaceuticals, Inc.
- SciFluor Life Sciences, LLC
- SK Biopharmaceuticals Co., Ltd.
Partial Seizure - Drug Profiles:
- pregabalin CR
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=231459 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases:
May 01, 2014: Kyowa Hakko Kirin Announces Launch Of New Formulation Of Topina, an Antiepileptic Agent
Apr 29, 2014: Sunovion Pharmaceuticals Presents Data on Aptiom (eslicarbazepine acetate) at 66th American Academy of Neurology Annual Meeting
Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of Neurology's 66th Annual Meeting
Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional Benefit Assessment
Jan 22, 2014: Zonegran Reimbursed in Switzerland as Monotherapy Treatment for Adults With Newly Diagnosed Partial Epilepsy
Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S.
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA (perampanel) CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older
Dec 09, 2013: Sunovion Pharmaceuticals Presents Phase 3 Pooled Analysis Of Once-Daily Aptiom As Adjunctive Treatment For Partial-Onset Seizures
Dec 09, 2013: Sunovion Pharmaceuticals Presents Positive Results From Two Phase 3 Studies of Once-Daily Aptiom as Monotherapy Treatment for Partial-Onset Seizures
Browse more reports on ENT Therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ent-therapeutics .
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.